Article
Ranibizumab (Lucentis®) as adjuvant for rubeosis and neovascular glaucoma
Search Medline for
Authors
Published: | June 15, 2011 |
---|
Outline
Text
Purpose: To evaluate prospectively the effect of intraocular ranibizumab (Lucentis®) as adjuvant treatment in patients with rubeosis (R) and secondary neovascular glaucoma (NG).
Methods: Ten eyes with NG and 10 eyes with rubeosis due to proliferative diabetic retinopathy (n=9) and ischemic central retinal vein occlusion (n=11) were treated with adjuvant Lucentis® injections (0.5 mg/0.05 ml). The main outcome measure was the change in degree of rubeosis at the 12 months follow-up (FU). Secondary outcomes included intraocular pressure (IOP), best corrected visual acuity (BCVA), numbers of additional interventions or antiglaucoma medications, the gonioscopical status of the anterior chamber angle and safety.
Results: In the R-group 3.6 injections (mean) and in the NG-group 2.5 injections of Lucentis® were administered. Additional treatments were photocoagulation (n=18 eyes), cyclodestructive procedures (n=9), cryopexy (n=3), and vitrectomy (n=1). A significant reduction of rubeosis was evident in both groups. The mean stage of rubeosis was 3.3±0.7 in the R-group and 3.56±0.88 in the NG-group at baseline and decreased significantly to 0.22±0.44 (R-group) and 0.89±1.17 (NG-group) after 9 months (p<0.05), respectively. In the NG-group the mean IOP was 42.1±14.0 mmHg at baseline which decreased rapidly (18.4±13.0 mmHg at day 14, p<0.05). At month-9 mean IOP was 13.8±4.9 mmHg (p<0.05). BCVA of this group (1.69, logMAR) was non-significantly improved accounting for 1.4 (logMAR) at month-9 (p>0.05). In the R-group no significant change of IOP was observed (p>0.05). Mean baseline BCVA (0.83, logMAR) was significantly improved after 6 months (0.63, logMAR) and was stabilized at this level (p<0.05).
Conclusions: Lucentis® is beneficial as adjuvant treatment in neovascular glaucoma and rubeosis due to ist anti-angiogenic properties and ist ability to prevent progression/establishment of angular obstruction.